[go: up one dir, main page]

ATE307808T1 - Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser - Google Patents

Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser

Info

Publication number
ATE307808T1
ATE307808T1 AT00918139T AT00918139T ATE307808T1 AT E307808 T1 ATE307808 T1 AT E307808T1 AT 00918139 T AT00918139 T AT 00918139T AT 00918139 T AT00918139 T AT 00918139T AT E307808 T1 ATE307808 T1 AT E307808T1
Authority
AT
Austria
Prior art keywords
active agent
stabilized
formulation
composition
water
Prior art date
Application number
AT00918139T
Other languages
English (en)
Inventor
David F Erkoboni
Ronald S Vladyka Jr
Pamela R Stergios
Original Assignee
Scherer Technologies Inc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Inc R P filed Critical Scherer Technologies Inc R P
Application granted granted Critical
Publication of ATE307808T1 publication Critical patent/ATE307808T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00918139T 1999-03-24 2000-03-20 Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser ATE307808T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12591499P 1999-03-24 1999-03-24
US14968099P 1999-08-19 1999-08-19
PCT/US2000/007298 WO2000056726A1 (en) 1999-03-24 2000-03-20 Improved aqueous solubility pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ATE307808T1 true ATE307808T1 (de) 2005-11-15

Family

ID=26824087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918139T ATE307808T1 (de) 1999-03-24 2000-03-20 Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser

Country Status (14)

Country Link
US (3) US6497905B1 (de)
EP (1) EP1163234B1 (de)
JP (1) JP2003531099A (de)
CN (1) CN1156461C (de)
AT (1) ATE307808T1 (de)
AU (1) AU3900300A (de)
BR (1) BR0009176A (de)
CA (1) CA2362728C (de)
DE (1) DE60023465T2 (de)
DK (1) DK1163234T3 (de)
ES (1) ES2251985T3 (de)
IL (2) IL145140A0 (de)
TW (1) TWI245644B (de)
WO (1) WO2000056726A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2381453A (en) * 1999-08-31 2003-05-07 Bradford Particle Design Ltd Active/polymer coformulations
WO2001078721A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Aβ42 LOWERING AGENTS
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
CN100512798C (zh) * 2000-12-22 2009-07-15 巴克斯特国际公司 亚微米颗粒悬浮液制备方法
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
AU2003209182A1 (en) * 2002-01-08 2003-07-24 Can Technologies, Inc. Encapsulation by coating with a mixture of lipids and hydrophobic, high melting point compounds
CA2460682C (en) 2002-02-28 2010-11-30 Japan Tobacco Inc. Ester compound and medical use thereof
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
DE10247037A1 (de) * 2002-10-09 2004-04-22 Abbott Gmbh & Co. Kg Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
EP1603548A4 (de) * 2003-02-05 2007-10-10 Myriad Genetics Inc Verfahren und zusammensetzung zur behandlung neurodegenerativer erkrankungen
BRPI0412190A (pt) * 2003-07-01 2006-08-22 Pharmacia & Upjohn Co Llc sólidos com camada de difusão modulada
HU227142B1 (en) * 2003-07-02 2010-08-30 Egis Gyogyszergyar Nyilvanosan Capsule of improved release containing fluconazole
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1669345A4 (de) 2003-08-29 2008-02-20 Japan Tobacco Inc Esterderivate und deren medizinische verwendung
US7413690B1 (en) 2003-10-29 2008-08-19 The University Of Mississippi Process and apparatus for producing spherical pellets using molten solid matrices
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
KR20070004036A (ko) * 2004-04-29 2007-01-05 키스톤 리테이닝 월 시스템스, 아이엔씨 벽, 옹벽 및 그 외 유사한 것을 위한 베니어
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
CN100430055C (zh) * 2005-11-11 2008-11-05 天津泰普药品科技发展有限公司 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
JP2007308479A (ja) 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 固体分散体製剤
EP2046119A2 (de) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Behandlung von psychiatrischen störungen
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
EP2334845A2 (de) * 2008-10-06 2011-06-22 Katholieke Universiteit Leuven K.U. Leuven R&D Funktionelle schichten von biomolekülen und lebenden zellen und neues system zu ihrer herstellung
EP2376068A2 (de) 2008-12-15 2011-10-19 Banner Pharmacaps, Inc. Verfahren zur verbesserung der freisetzung und absorption von wasserunl?slichen wirkstoffen
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20110150993A1 (en) * 2009-12-22 2011-06-23 Fmc Corporation Fine Particle Croscarmellose and Uses Thereof
EP2601973A1 (de) * 2011-12-09 2013-06-12 Laboratoires SMB SA Trockenpulverformulierung eines Azolderivats zum Inhalieren
JP2014122328A (ja) * 2012-11-22 2014-07-03 Shin Etsu Chem Co Ltd 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法
GB201602579D0 (en) 2016-02-12 2016-03-30 Mihranyan Albert New compositions
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US20190142756A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Drug formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US5118799A (en) 1987-05-12 1992-06-02 Pharmacin Corporation Process for converting crystalline erythromycin ethylsuccinate into stable amorphous erythromycin ethylsuccinate
EP0462066A1 (de) 1990-06-15 1991-12-18 Warner-Lambert Company Amorphes Gemfibrozil
JP2829794B2 (ja) * 1991-02-08 1998-12-02 エスエス製薬 株式会社 徐放性経口投与型プラノプロフェン製剤
US5208015A (en) 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
ES2091019T3 (es) 1992-02-12 1996-10-16 Janssen Cilag S P A Formulaciones liposomicas de itraconazol.
CZ286619B6 (cs) 1992-03-18 2000-05-17 Janssen Pharmaceutica N. V. Stereoisomerické formy itrakonazolu a saperkonazolu, způsob jejich výroby, jejich komplexy, způsob výroby těchto komplexů, farmaceutické přípravky a způsob jejich výroby
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1256386B (it) * 1992-11-13 1995-12-04 Luigi Boltri Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5565478A (en) 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US5976555A (en) 1994-09-07 1999-11-02 Johnson & Johnson Consumer Products, Inc. Topical oil-in-water emulsions containing retinoids
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
US5646151A (en) * 1996-03-08 1997-07-08 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
AP1227A (en) 1997-03-26 2003-11-24 Janssen Pharmaceutica Nv Pellets having a core coated with an antifungal and a polymer.
US5813416A (en) 1997-04-03 1998-09-29 Rudolph; James M. File with sanitizing agent
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제

Also Published As

Publication number Publication date
JP2003531099A (ja) 2003-10-21
US20020037324A1 (en) 2002-03-28
TWI245644B (en) 2005-12-21
EP1163234A4 (de) 2003-05-02
AU3900300A (en) 2000-10-09
CN1156461C (zh) 2004-07-07
DE60023465T2 (de) 2006-07-20
CA2362728A1 (en) 2000-09-28
US20020012706A1 (en) 2002-01-31
ES2251985T3 (es) 2006-05-16
CA2362728C (en) 2009-06-23
US6511681B2 (en) 2003-01-28
IL145140A (en) 2006-08-20
US6379707B2 (en) 2002-04-30
CN1379768A (zh) 2002-11-13
EP1163234A1 (de) 2001-12-19
EP1163234B1 (de) 2005-10-26
IL145140A0 (en) 2002-06-30
US6497905B1 (en) 2002-12-24
DK1163234T3 (da) 2006-02-27
WO2000056726A1 (en) 2000-09-28
BR0009176A (pt) 2001-12-18
DE60023465D1 (de) 2005-12-01

Similar Documents

Publication Publication Date Title
ATE307808T1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
ES2561108T3 (es) Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
ES2620413T3 (es) Formulaciones veterinarias antihelmínticas tópicas
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
ITMI20021392A1 (it) Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
PE20001049A1 (es) Complejos estables de compuestos escasamente solubles
ES2193658T3 (es) Procedimiento para la preparacion de formulaciones acuosas para uso oftalmico.
YU23599A (sh) Stabilizovani antihistaminski sirup
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
CA2414063A1 (en) Highly concentrated stable meloxicam solutions
DE60017361D1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
MXPA05005046A (es) Formulaciones parasiticidas topicas y metodos de tratamiento.
ATE245968T1 (de) Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung
CA2380757A1 (en) Pharmaceutical agent comprising a benzamide derivative as active ingredient
EP1219296A4 (de) Mittel zur hemmung der sebumproduktion
WO2002009717A1 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
ES2127725T3 (es) Composiciones agricolas pulverizables.
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
ATE258046T1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
ATE275577T1 (de) Quinapril magnesium enthaltende, pharmazeutisch wirksame zusammensetzung
BR0113055A (pt) Preparação sólida altamente absorvìvel
FR2809958B1 (fr) Composition pharmaceutique sous forme liquide destinee a l'administration par voie orale d'un principe actif, ayant un gout desagreable, notamment un gout amer
DE68901852D1 (de) Primycin-loesungen.
WO2005123085A1 (es) Solución acuosa de risperidona para administración oral

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1163234

Country of ref document: EP

REN Ceased due to non-payment of the annual fee